Provided by Tiger Trade Technology Pte. Ltd.

Oric Pharmaceuticals Inc.

11.13
-0.0300-0.27%
Volume:1.50M
Turnover:16.76M
Market Cap:1.12B
PE:-7.57
High:11.62
Open:11.22
Low:10.59
Close:11.16
52wk High:14.93
52wk Low:3.90
Shares:100.36M
Float Shares:86.55M
Volume Ratio:0.89
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4700
EPS(LYR):-1.4747
ROE:-41.27%
ROA:-26.17%
PB:2.91
PE(LYR):-7.55

Loading ...

Oric Pharmaceuticals Currently Down Eight Consecutive Days, On Track for Longest Losing Streak Since June 2024 -- Data Talk

Dow Jones
·
Dec 17, 2025

ORIC Pharmaceuticals (ORIC): Valuation Check After Encouraging Enozertinib Phase 1b Lung Cancer Data

Simply Wall St.
·
Dec 09, 2025

Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush

Dow Jones
·
Dec 08, 2025

Oric Pharmaceuticals Grants Stock Options and Restricted Stock Units to New Employees

Reuters
·
Dec 06, 2025

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 06, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06, 2025

Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC Patients with EGFR Mutations

Reuters
·
Dec 05, 2025

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

GlobeNewswire
·
Dec 05, 2025

Oric Pharmaceuticals Showcases Enozertinib Data at ESMO Asia Congress 2025

Reuters
·
Dec 04, 2025

Oric® Pharmaceuticals Announces Enozertinib (Oric-114) Late-Breaking Oral Presentations in Egfr Atypical and Egfr Exon 20 Nsclc at the Esmo Asia Congress 2025

THOMSON REUTERS
·
Dec 04, 2025

ORIC Pharmaceuticals (ORIC): Assessing Valuation as New Enozertinib Clinical Data Sparks Investor Interest

Simply Wall St.
·
Dec 02, 2025

Oric Pharmaceuticals Unveils Phase 1b Data for Enozertinib in HER2 Exon 20 NSCLC at ESMO Asia 2025

Reuters
·
Dec 01, 2025

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

GlobeNewswire
·
Nov 25, 2025

Stock Track | Oric Pharmaceuticals Surges 5.92% Pre-market on Positive Analyst Coverage

Stock Track
·
Nov 20, 2025

Oric Pharmaceuticals Initiated at Outperform by Evercore ISI Group

Dow Jones
·
Nov 20, 2025

Oric Pharmaceuticals initiated with an Outperform at Evercore ISI

TIPRANKS
·
Nov 20, 2025

ORIC Pharmaceuticals Q3 Net Income USD -32.587 Million

Reuters
·
Nov 20, 2025

Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Nov 20, 2025

Oric Pharmaceuticals Initiated at Peer Perform by Wolfe Research

Dow Jones
·
Nov 19, 2025

Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan

TIPRANKS
·
Nov 18, 2025